TREOSULFAN TILLOMED 5g powder infusion solution medication leaflet

L01AB02 treosulfan • Antineoplastic and immunomodulating agents | Alkylating agents | Alkyl sulfonates

Treosulfan is an alkylating agent primarily used as part of conditioning regimens for hematopoietic stem cell transplantation. It works by forming covalent bonds with DNA, leading to the inhibition of cellular replication and the destruction of malignant or existing hematopoietic cells.

Treosulfan is administered intravenously, usually in combination with other drugs such as fludarabine, to prepare patients for transplantation. It is particularly used in patients who cannot tolerate more intensive conditioning regimens due to its lower toxicity profile.

Common side effects include myelosuppression, nausea, vomiting, diarrhea, and fatigue. In rare cases, severe adverse reactions such as hepatotoxicity, pulmonary function impairment, or serious infections may occur. Careful monitoring of hematological parameters and organ function is essential during treatment.

Treosulfan is an important therapeutic option for patients requiring stem cell transplantation, contributing to increased success rates and reduced associated risks.

General data about TREOSULFAN TILLOMED 5g

Substance: treosulfan

Date of last drug list: 01-08-2019

Commercial code: W65961001

Concentration: 5g

Pharmaceutical form: powder infusion solution

Quantity: 1

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: MIAS PHARMA LIMITED - IRLANDA

Holder: LABORATORIOS TILLOMED SPAIN S.L. - SPANIA

Number: 15221/2023/01

Shelf life: 2 years

Concentrations available for treosulfan

5000mg, 5g

Other substances similar to treosulfan